DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "World Implantable Drug Delivery Devices Market - Opportunities and Forecasts, 2014 - 2022" report to their offering.
Implantable drug delivery devices are the medical devices which enable site specific drug administration. It also helps in minimizing the doses of drug in order to reduce potential side effects. These devices facilitate sustained release of a therapeutic agent. These implantable devices are gaining edge over conventional oral or parenteral dosage forms due to site specific and sustained release therapeutic action of implantable devices, which further minimize the side-effects associated with the drug.
The major factors driving the growth of this market are growing incidences of target disease such as diabetic retinopathy, prostate cancer, cardiovascular diseases and chronic diseases. Rising cases of unwanted pregnancies and growing aging population also supplement the growth of this market. However, cost associated with the use of these devices has restricted the market growth.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America is the largest market due to growing aging population and prevalence of target disease such as diabetic retinopathy and chronic diseases. Asia-Pacific is considered to be the fastest-growing market due to high disposable income in emerging nations.
Companies Mentioned:
- Bayer Healthcare
- Boston Scientific Corporation
- Allergan Inc.
- Medtronic Inc.
- Merck
-
Bausch
-
Lomb, Inc.
-
Abbott laboratories
For more information visit http://www.researchandmarkets.com/research/jjbv66/world_implantable
